- Home
- CLLS vs SRG Comparison
CLLS vs SRG Comparison
Compare CLLS & SRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$4.39
HOLD
Current Price
$3.35
Company Overview
Basic Information| Metric | CLLS | SRG |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.0M | 236.0M |
| IPO Year | 2007 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CLLS | SRG |
|---|---|---|
| Price | $4.39 | $3.35 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | 133.9K | ★ 188.3K |
| Earning Date | 11-07-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $82,551,000.00 | $17,406,000.00 |
| Revenue This Year | $32.58 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 129.04 | N/A |
| 52 Week Low | $1.10 | $2.43 |
| 52 Week High | $5.48 | $4.56 |
Technical Indicators
Market Signals| Indicator | CLLS | SRG |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 40.85 |
| Support Level | $4.47 | $3.38 |
| Resistance Level | $5.45 | $3.68 |
| Average True Range (ATR) | 0.30 | 0.13 |
| MACD | -0.12 | 0.00 |
| Stochastic Oscillator | 31.17 | 22.45 |
Price Performance
Historical Comparison CLLS
SRG
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.